Health and Healthcare

Genentech Shares Hang In Despite Soft Key Drug Sales (DNA)

Shares of Genentech Inc. (NYSE: DNA) are trading slightly lower after reporting a gain in earnings.  The biotech giant posted $0.74 net EPS, but non-GAAP EPS excluding special items was $0.84 EPS on revenues of $3.06 Billion.  First Call showed estimates at $0.82 EPS on $3.11 Billion in revenues, which is a beat on earnings but slightly light on revenues.

CNBC gave some individual figures for expectations on its individual drugs, and again these were light of many estimates on each target out there:

  • Avastin sales were $600 million in the quarter, compared with an expected $629 million;
  • Rituxan sales reached $605 million, under estimates of $607 million;
  • Herceptin salers were $339 million, under estimates of $343 million;
  • Lucentis sales reached $198 million, under forecasts of $202 million.

Shares closed up 0.3% at $78.00 in regular trading today, and shares are actually up marginally by 0.4% in after-hours.  That is better than the initial drop of 1% in after-hours trading after the news was out.

Jon C. Ogg
April 10, 2008

Essential Tips for Investing (Sponsored)

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.